Figure 2.

Cumulative incidence curves of IS/SE (A), all major bleeding (B), ICH (C), and major GI bleeding (D) for liver cirrhotic patients with nonvalvular atrial fibrillation according to initiated treatment after propensity score–based stabilized weighting. The NOAC group showed risk of IS/SE comparable to that of the warfarin group after adjustment. For the safety outcome, the NOAC group showed significantly lower risk of major GIB and all major bleeding than the warfarin group. GIB indicates gastrointestinal bleeding; ICH, intracranial hemorrhage; IS/SE, ischemic stroke/systemic embolism; NOAC, non–vitamin K antagonist oral anticoagulant.